Figure 2.

Trajectory of functional and cognitive abilities across 6 months of treatment. In the present trial participants that received active treatment demonstrated slower cognitive decline on the MMSE and ADCS-ADL over the course of 6 months of treatment compared to participants that received sham treatment. (A) Forest plot of LSMeans (SD) of efficacy outcomes to explore the association between the sham and active arms for each subgroup. Statistical values are represented in the table (N, LSMeans, and P-values). There was a significant difference between the active and sham groups trajectories as measured by the (B) MMSE (p = 0.042). Significant differences between active and sham arms at the end of the 6-month trial can be observed across scores on the ADCS-ADL (C) total (p = 0.0004), (D) basic (p = 0.004), and (E) instrumental (p = 0.0001). Functional abilities in the active group were retained during the 6 months of treatment compared to significant worsening in the sham group. *p < 0.05, **p < 0.005, ***p < 0.0005. Arrows point in the direction of worsening scores.